INCYTE DERMATOLOGY


Associated tags: Atopic dermatitis, Lichen planus, Vitiligo, Prurigo nodularis, JAK, Dermatology, Hidradenitis suppurativa, Research, Patient, Health, Pharmaceutical, Biotechnology, Clinical Trials, Pharmaceutical industry, Safety, Inflammation, Week

New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting

Retrieved on: 
Monday, March 4, 2024

Incyte (Nasdaq:INCY) today announced multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2024 American Academy of Dermatology (AAD) Annual Meeting, held March 8-12, 2024, in San Diego.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2024 American Academy of Dermatology (AAD) Annual Meeting, held March 8-12, 2024, in San Diego.
  • “We are pleased to convene at this year’s AAD Annual Meeting and share data, including two late-breaking presentations, from our growing dermatology portfolio,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte.
  • “Our presence at this year’s meeting showcases Incyte’s commitment to find solutions for patients where there continues to be critical unmet needs.
  • They will also be published online via the Journal of the American Academy of Dermatology (JAAD) supplement in Fall 2024.

Data From Incyte’s Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)

Retrieved on: 
Friday, October 13, 2023

Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring new data from the company’s clinical program on povorcitinib, an investigational oral JAK-1 inhibitor, have been accepted for oral presentation at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) held October 13-15 in Phoenix.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring new data from the company’s clinical program on povorcitinib, an investigational oral JAK-1 inhibitor, have been accepted for oral presentation at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) held October 13-15 in Phoenix.
  • ET)
    HiSQoL Changes Among HiSCR Responders and Nonresponders in a Phase 2 Study of Povorcitinib (Session: Clinical Research - Observational, Trials, and Treatment.
  • ET)
    Baseline Patient Characteristics Associated with Achieving HiSCR with Povorcitinib: Phase 2 Secondary Analysis (Session: Clinical Research - Observational, Trials, and Treatment.
  • ET)
    For full session details and data presentation listings, please see the SHSA 2023 ( https://shsa.joynsymposium.com/conference_hall ) online program.

Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis

Retrieved on: 
Friday, October 13, 2023

Incyte (Nasdaq:INCY) today announced expanded results from the pivotal Phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream (Opzelura®) in children (age ≥2 to

Key Points: 
  • Incyte (Nasdaq:INCY) today announced expanded results from the pivotal Phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream (Opzelura®) in children (age ≥2 to
  • "The TRuE-AD3 data presented today at EADV reinforce the strong safety and efficacy profile of ruxolitinib cream and its potential to treat younger age groups,” said Jim Lee, M.D., Group Vice President, Inflammation & AutoImmunity, Incyte.
  • Ruxolitinib cream was well tolerated with no serious infections, major adverse cardiovascular events (MACE), malignancies or thromboses reported during the 8-week vehicle-controlled period.
  • The most common treatment-related adverse event observed in the ruxolitinib cream arms was application site pain (2.7% vs 0% in vehicle arm).

New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients

Retrieved on: 
Wednesday, October 11, 2023

These long-term data highlight encouraging updates for an important sub-group of patients with nonsegmental vitiligo, those who initially showed limited or no response to treatment,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & AutoImmunity, Incyte.

Key Points: 
  • These long-term data highlight encouraging updates for an important sub-group of patients with nonsegmental vitiligo, those who initially showed limited or no response to treatment,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & AutoImmunity, Incyte.
  • Opzelura is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.
  • The overall prevalence of the condition is estimated to be approximately 2-3 million2, with the majority of patients (approximately 85%) suffering from nonsegmental vitiligo3.
  • Vitiligo can occur at any age, although many patients with vitiligo will experience initial onset before the age of 304.

Incyte and Mandy Moore Partner to Empower People with Atopic Dermatitis to Find Their Moments of Clarity

Retrieved on: 
Wednesday, October 11, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231011336627/en/
    As someone who also lives with eczema, Mandy Moore understands the challenges of the condition.
  • Through Moments of Clarity, Mandy encourages others with eczema to take charge of their health and talk to their dermatologists about finding an appropriate treatment.
  • After seeing a dermatologist, I was diagnosed with eczema," said Mandy Moore.
  • “We are grateful to Mandy Moore for partnering with us and lending her voice to help others know they are not alone in their journeys.”
    * Mandy Moore has been compensated for her participation.

Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Retrieved on: 
Wednesday, October 11, 2023

Incyte (Nasdaq:INCY) today announced new 52-week data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib (INCB54707), an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced new 52-week data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib (INCB54707), an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo.
  • “These 52-week results further support earlier data and reinforce the efficacy profile and potential of povorcitinib as an oral treatment for patients with extensive nonsegmental vitiligo,” said Kurt Brown, M.D., Vice President and Povorcitinib Global Program Head, Incyte.
  • “At Incyte, we are deeply committed to addressing unmet needs in the vitiligo community and understanding how this disease can affect patients’ lives.
  • Vitiligo can occur at any age, although many patients with vitiligo will experience initial onset before the age of 304.

Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress

Retrieved on: 
Friday, September 29, 2023

Incyte (Nasdaq:INCY) today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2023 held October 11-14 in Berlin.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2023 held October 11-14 in Berlin.
  • “Collectively, the data at this year's Congress, which also include new late-breaking data for povorcitinib in vitiligo, emphasize our ongoing efforts to advance treatment options for the Dermatology community."
  • Key abstracts from Incyte-sponsored programs include:
    Efficacy and Safety of Povorcitinib for Extensive Vitiligo: 52-Week Results from a Double-Blinded, Placebo-Controlled, Dose-Ranging Phase 2b Study (Abstract #6749.
  • ET)
    A Phase 3 Study of Ruxolitinib Cream in Children Aged 2–

Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis

Retrieved on: 
Tuesday, July 11, 2023

Incyte (Nasdaq:INCY) today announced positive topline results from its randomized, vehicle-controlled, pivotal Phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream (Opzelura®) in children (age ≥2 to

Key Points: 
  • Incyte (Nasdaq:INCY) today announced positive topline results from its randomized, vehicle-controlled, pivotal Phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream (Opzelura®) in children (age ≥2 to
  • The study met its primary endpoint and showed significantly more patients treated with ruxolitinib cream 0.75% and 1.5% achieved Investigator’s Global Assessment Treatment Success (IGA-TS) than patients treated with vehicle control (non-medicated cream).
  • The overall safety profile of ruxolitinib cream is consistent with previous data, and no new safety signals were observed.
  • "We have already seen the benefit that ruxolitinib cream can have among adult and adolescent patients with atopic dermatitis in the TRuE-AD1 and TRuE-AD2 studies, and this new positive data reinforces the potential of ruxolitinib cream to offer children a much-needed effective, non-steroidal topical therapy.

MHRA Grants Marketing Authorisation for Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents

Retrieved on: 
Wednesday, July 5, 2023

Incyte Biosciences UK today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation for Opzelura® (ruxolitinib) cream 15mg/g for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Key Points: 
  • Incyte Biosciences UK today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation for Opzelura® (ruxolitinib) cream 15mg/g for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
  • Opzelura is the first and only approved treatment in the United Kingdom (UK) to offer eligible patients with non-segmental vitiligo support for repigmentation.
  • “Today’s MHRA approval is welcome news for dermatologists and people with vitiligo seeking treatment who until now have had limited options.
  • “We are delighted to announce the MHRA approval of Opzelura for people living with non-segmental vitiligo with facial involvement,” said Peter Williams, General Manager, Incyte United Kingdom and Ireland.

Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) Cream

Retrieved on: 
Monday, May 1, 2023

These data were featured in a poster presentation (Poster #396) at the Revolutionizing Atopic Dermatitis (RAD) Conference, held from April 29-May 1 in Washington, D.C.

Key Points: 
  • These data were featured in a poster presentation (Poster #396) at the Revolutionizing Atopic Dermatitis (RAD) Conference, held from April 29-May 1 in Washington, D.C.
  • Results showed that patients with AD treated with Opzelura experienced a rapid and substantial improvement in itch, which was sustained and further improved through 28 days of treatment.
  • "We are pleased that the SCRATCH-AD results further emphasize the rapid impact of Opzelura on itch reduction and reinforce its profile as an effective, well-tolerated topical non-steroidal treatment for AD."
  • “I am encouraged by these results showing rapid and substantial itch reduction among AD patients treated with Opzelura, and its potential to quickly alleviate this burdensome symptom for patients.”